...
Editor in Chief's Message
Review Articles
2-8
Download
Each year, over three-fourths of the women of reproductive age in the United States seek family planning services from primary care clinicians. Women and their doctors should be informed of all effective family planning options and their respective effects on a woman's reproductive healt...
9-16
Download
Environmental allergens that induce a type I immune hypersensitivity present a widespread and significant reduction in the quality of life for our patients while imposing a stifling cost upon health care and the economy. A prompt, accurate clinical diagnosis with an appropriate managemen...
17-23
Download
Jaundice is a potentially life-threatening condition that continues to affect at-risk newborns, accounting for continued hospital readmissions. As family physicians, we should be cognizant of neonates who may be at risk for jaundice, including those with pathologic jaundice as well as ne...
24-26
Download
Langerhans cell histiocytosis (LCH) is a relatively rare dendritic cell disorder with an unclear etiology. The incidence is 2:1 million and it is most commonly seen in children from 5 to 10 years of age. The diagnosis is confirmed by biopsy with treatment options varying from simple obse...
Supplement
33-42
Download
The sheer numbers of patients with type 2 diabetes, a chronic illness with multifactorial pathophysiology, common comorbidities, exacerbated by an obesity epidemic and a lack of specialists to care for them may seem daunting. However, new treatment options and treatment guidelines that t...
43-50
Download
Incretin-based therapies include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) based therapies. Both classes of agents are predicated on the knowledge that GLP-1, a gut-derived hormone, plays a major role in glucose homeostasis, a fact that has been...
51-57
Download
Adding glucagon-like peptide-1 (GLP-1) receptor agonists to insulin therapy for patients with type 2 diabetes mellitus (T2DM): why and how patients with T2DM who progress to insulin therapy usually do so by starting with a single injection of a long-acting insulin analog, added to oral a...